Westside Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Westside Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Hold	1,500	–	–	﹤0.01%	1018
2026 Q1	$14.3K	Buy	1,500 +500	+50%	+$3.88K	﹤0.01%	1010
2025 Q4	$7.8K	Buy	1,000 +500	+100%	+$3.62K	﹤0.01%	1150
2025 Q3	$3.79K	Hold	500	–	–	﹤0.01%	1289
2025 Q2	$4.48K	Hold	500	–	–	﹤0.01%	1159
2025 Q1	$3.75K	Hold	500	–	–	﹤0.01%	820
2024 Q4	$3.76K	Hold	500	–	–	﹤0.01%	814
2024 Q3	$3.8K	Hold	500	–	–	﹤0.01%	814
2024 Q2	$3.09K	Hold	500	–	–	﹤0.01%	832
2024 Q1	$2.54K	Hold	500	–	–	﹤0.01%	809
2023 Q4	$3K	Hold	500	–	–	﹤0.01%	760
2023 Q3	$3.54K	Hold	500	–	–	﹤0.01%	730
2023 Q2	$3.52K	Buy	+500	New	+$4.01K	﹤0.01%	737

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Westside Investment Management's BCRX Position: Q2 2026 in Review

Westside Investment Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 1,500 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Westside Investment Management first reported a position in BCRX in Q2 2023 and has held it in 13 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Westside Investment Management held 1,500 shares of BioCryst Pharmaceuticals worth $15K as of Q2 2026.
Westside Investment Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Westside Investment Management's portfolio in Q2 2026, its #1018 holding.
Westside Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Westside Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.